Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01924689 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
A Phase 1 study, sponsored by BioMed Valley Discoveries.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01924689 is a Phase 1 study that has completed, run by BioMed Valley Discoveries. The registered enrollment target is 24 participants.
The verdict
NCT01924689, a Phase 1 study, has completed, sponsored by BioMed Valley Discoveries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This protocol will examine the safety of intratumoral administration of Clostridium Novyi-NT spores in patients with treatment-refractory solid tumor malignancies. This investigational study will measure anti-tumor activity of C. novyi-NT administered intratumoral in patients with treatment-refractory solid tumor malignancies.
Interventions
- BIOLOGICAL Clostridium novyi-NT spores
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-10 |
| Est. Completion | 2017-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01924689
The ClinicalTrials.gov registry entry for NCT01924689 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMed Valley Discoveries, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Clostridium novyi-NT spores is the first listed.
NCT01924689 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01924689 about?
NCT01924689 is a clinical study titled "Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies". This protocol will examine the safety of intratumoral administration of Clostridium Novyi-NT spores in patients with treatment-refractory solid tumor malignancies. This investigational study will measure anti-tumor activity of C. novyi-NT administered intratumoral in patients with treatment-refracto...
What is the current status of trial NCT01924689?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-10. Estimated completion is 2017-10-31.
What interventions are being tested in trial NCT01924689?
The interventions under investigation include: Clostridium novyi-NT spores (BIOLOGICAL).
Who is sponsoring clinical trial NCT01924689?
This trial is sponsored by BioMed Valley Discoveries, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.